SPANISH FRENCH ENGLISH ITALIAN ARAB About Ovobank 2 Ovobank is the first donor Egg Bank in Europe, created to meet the growing need for donor oocytes, helping to optimize fertility treatments and making it easier for patients and future families.
Legality
Both Ovobank and the centers on which it is supported (FIV Marbella and Ovoclinic) comply with the Spanish Assisted Did you know that Reproduction Law 14/2006, as well as Royal Ovobank collaborates with Decree-Law 09/2014 and 9/2017 on cell and tissue more than 200 fertility bank in quality system (both transpositions to the centers and can send your national territory of Euro- pean directives 2004/23 / oocytes wherever you want? CE, 2006/17 / EC and 2006/86 / EC, where the Si desea ser centro colaborador, obtaining, donation, contacte con nosotros evaluation, traceability, storage and distribution of donor gametes are regulated), having obtai- ned the authorization as a bank of human oocytes by the Spanish Health Authorities.
Ovobank has the most advanced facilities, as well as state-of-the-art equipment to be able to provide a maximum quality service within the FIV Marbella and Ovoclinic assisted reproduction centers. In addition, Ovobank has five strategic donor recruitment points in the Spanish geography: Marbella, Malaga, Madrid, Barcelona and Granada. Our bank is able to respond to the needs of the collaborating centers quickly and efficiently. Ovobank´s oocyte vitrification process is performed by qualified and trained personnel in the field of cryobiology, and the means and products used comply with European regulations. All this results in the oocytes being processed in the best possible conditions, conserving all their potential in order to offer a quality service and with the maximum guarantee of success.
Ovobank - The first european donor egg bank Why choose Ovobank?
Because we ensure the Because of our exhaustive highest quality of vitrified process of donor oocytes. selection. 3
For our large pool of donors For our advanced and rigorous and the high number of system of transport, vitrified oocytes in stock. conservation and traceability.
Because of our high response For our staff, speed, thanks to the Ovotracker specialized in assisted system and the use of vitrified reproduction. oocytes.
How to use Ovobank
Contact Ovobank to register as a collaborating center. You can do it either by 01 calling +34 951 087 975 or by email at [email protected].
Once the collaboration contract is signed, we will provide you with a username 02 and password to access our Ovotracker system, where you can complete the application with the physical and immunological characteristics of the recipient couple. After studying it, our Donor Coordination Department will make a proposal with the most compatible donors for that couple (or patient).
03 You can have your oocytes order in a period of 24/48 hours, in the case of vitrified oocytes.
At the same time, you can download through Ovotracker (through restricted 04 access with your personal password) the report with the data of the donor as well as the results of the analytical, gynecological, psychological and genetic studies carried out in accordance with the provisions of Law 14 / 2006, Royal Decree 1301/2006, the European guidelines and the signed collaboration agreement.
www.ovobank.com Vitrification
4
Vitrification is the most effective oocyte cryopreservation method and the one which has demonstrated the highest survival rate to date (up to 97%). It is so safe and simple that it can be done in all assisted reproduction clinics, as long as the devitrification protocols set by Ovobank are respected. Vitrification has revolutionized the world of cryobiology, allowing both oocytes and embryos to be cryopreserved with great success. Thawing is simple and fast and it is only necessary to have devitrification kits and strictly follow their protocol. If necessary, it is possible for one of our specialized biologists to travel to the collaborating center to perform the devitrification of the oocytes.
Shipping
The oocyte batches are transported in DRY SHIPPER liquid nitrogen cryo-containers, specially made for the transportation of cells and tissues, at -196ºC. The oocytes are in turn classified by a system of rods and goblets, which makes it very easy to identify the batches without harming their temperature conditions. Our technology, for peace of mind We have technology and equipment which is unique in Europe, thanks to which you can know in real time the conditions under which the cells travel (through our Ovotracker app), as well as the GPS location of the container at all times.
Ovobank - The first european donor egg bank The 3 keys to succes of Ovobank
Ovobank has five strategic points of recruitment in the Spanish geography: Marbella, Málaga, Madrid, Diversity Barcelona and Granada, covering more than 7 million people of 150 different nationalities, so it has donors of all races, nationalities, blood groups and phenotypes. 5
With the use of vitrified oocytes from donors, the collaborator center avoids the process of donor selection, medical tests and stimulation phases, since all this has been done previously by Ovobank. The patient will not have to endure waiting lists for the assignment of a donor, our team will be in charge of Availability finding the ideal donor. With the use of vitrified oocytes, Ovobank offers More than 300 peace of mind that the donor cycle will not be vitrified lots are available canceled. for emergencies. Thanks to all this, it is possible to schedule the treatment at the time you prefer. Most patients find this aspect of the use of vitrified donated oocytes particularly attractive, because it gives them more control over their treatment.
The use of Ovobank vitrified oocytes allows the treatment to adjust to your needs, promoting positive success. We guarantee, for each receiver, a variable number of Success mature oocytes, providing a high percentage of survival, transfer and freezing of surplus embryos. Using vitrified oocytes the costs of an egg donation cycle are reduced.
www.ovobank.com Ovobank’s donors
The majority of Ovobank donors are women The law Donation 6 between 18 and 30 years Both Ovobank, FIV Marbella and the The donation is performed within old, in good physical and Ovoclinic centers comply with the our facilities, which have the psychological health, Spanish Law of Assisted Reproduc- category of a hospital, therefore the tion 14/2006, as well as Royal risks are reduced to a minimum. The which are subjected to Decree-Law 09/2014, 09/2017 on cell extracted oocytes are immediately comprehensive and tissue bank in the quality system. treated by the laboratory personnel (Both transpositions of EU Directives). gynecological, for their vitrification. psichological, serological and genetic tests. Of the possible donors, only one third are selected, since Treatment the exclusion criteria are Exclusion criteria The objective of the treatment is very strict. the well-being of the donor, and Only 30% of all donors who therefore the medication is come to Ovobank to donate adjusted according to the eggs end up being declared Genetic hormonal study, the BMI and other fit, due to the completeness of the tests that are performed. matching characteristics. The Ovobank staff will see to the donors wellbeing. The Test of Genetic Compatibility or Genetic Matching allows to compare the genetic informa- Initial evaluation Medical check tion of the donor All donors undergo an initial evaluation interview to rule out Our donors medical review is with that of the inheritable psychopathies. In carried out by the gynecologist couple of the recei- addition, family and personal and consists of the following ving woman, in histories are analyzed for both studies: hormonal study, psychologicaland communicable complete gynecological review, order to avoid the analytics and serology. transmission of auto- diseases. somal recessive genetic diseases. This information will be compared by selecting the appro- Analysis Psychological study priate donor, so that Blood tests represent a Through an in-depth personal patient and donor fundamental step in this process: interview and psychological tests, do not share muta- pathological anatomy, blood carried out by our specialists, the existence of psychiatric and tions in the same count, biochemistry, coagulation, serology, blood analysis in real psychological disorders or genes. time, genetics test, etc... inadequate habits is ruled out.
Ovobank - The first european donor egg bank Procedure for the donor selection
1. 2. 3. 4. Informative Ginecologic Psicologic visit evaluation evaluation Blood tests
PATHOLOGICAL ANATOMY Smear Culture
HEMOGRAMAHEMOGRAM Erythrocyte series Red bood cells Mean corpuscular volume (MCV) Haemoglobin Mean Corpuscular Haemoglobin (MCH) Haematocrit Mean corpuscular haemoglobin conc. (MCHC) Red blod cell distribution width (RDW) 7 Leukocytes series White blood cells Lymphocytes Eosinophil Neutrophils Monocytes Basophils Platelet series Platelets Mean platelet volume (MPV)
Immunohematology Bood group Rhesus factor Rh
BIOCHEMISTRY
Creatinine ALT / GPT Glucose Total colesterol Urea AST / GOT Triglycerides HDL
COAGULATION Activated partial Prothrombin International Partial thromboplastine thromboplastine ratio activity ratio time (PTT) (APTT)
SEROLOGÍASEROLOGY Hepatitis B surface Antigen Hepatitis C Total antibodies HTLV I - II Hepatitis B surface Antibodies CMV IgG / IgM Zika IgM Hepatitis B Core Antibody IgG HIV-1 + HIV-2 Hepatitis B Core Antibody IgM Syphilis
BLOOD TESTS At the beginning of the stimulation. IN REAL TIME (PCR) x2 On the Pick up day.
HIV HEPATITIS B HEPATITIS C
SEROTECASERUM BANK
GENÉTICAGENETICS
Kariotipe G6PDH Cystic fibrosis Hemoglobin electrophoresis Chromosome fragile-Xt Genetic Compatibility Test*
* Recombine, Qgenomics, Igenomix, Precongen o Bioarray (ask about availability).
www.ovobank.com Genetic studies
In our constant search for the optimization of the level of safety of our donated oocytes, Ovobank (since December 1, 2016) performs on new donors the test for carriers of recessive mutations (Genetic Matching Test) , an innovative technique that allows us to minimize the transmission of genetic diseases to children born from the oocytes of our donors. This is achieved thanks to these tests: They allow us to exclude from our Egg Donation Program candidates carrying autosomal recessive mutations, including cystic fibrosis, Fragile-X, hemoglobinopathy, G6PDH, spinal muscular atrophy, alpha and beta thalassemia. In addition, in case the patients wish to do it, we can conduct a study of genetic compatibility between the donor and the husband of the recipient patient, which consists of analyzing the genetic information to ensure that the donor and the patient do not share any of the recessive mutations studied, thus minimizing the risk of transmission of a genetic disease to their offspring. Although most of our donors have already been studied with the "Recombine" test, we can add any diagnostic study at the request of our collaborating centers. 8 The number of mutations and diseases studied will depend on the genetic compatibility test performed:
3-Beta-Hydroxysteroid Dehydrogenase Deficiency X-Linked: PRPS1 Related Galactokinase Deficiency 3-Methylcrotonyl-CoA Carboxylase Deficiency: Chediak-Higashi Syndrome Gaucher Disease MCCA Related Cholesteryl Ester Storage Disease Gitelman Syndrome 3-Methylcrotonyl-CoA Carboxylase Deficiency: Choreoacanthocytosis Globoid Cell Leukodystrophy MCCB Related Choroideremia Glucose-6-Phosphate Dehydrogenase Deficiency 3-Methylglutaconic Aciduria: Type 3 Chronic Granulomatous Disease: CYBA Related Glutaric Acidemia: Type I 3-Phosphoglycerate Dehydrogenase Deficiency Chronic Granulomatous Disease: X-Linked Glutaric Acidemia: Type IIA 5-Alpha Reductase Deficiency Citrin Deficiency Glutaric Acidemia: Type IIB 6-Pyruvoyl-Tetrahydropterin Synthase Deficiency Citrullinemia: Type I Glutaric Acidemia: Type IIC 11-Beta-Hydroxylase-Deficient Congenital Adrenal Classical Galactosemia Glycine Encephalopathy: AMT Related Hyperplasia Cockayne Syndrome: Type A Glycine Encephalopathy: GLDC Related 17-Alpha-Hydroxylase Deficiency Cockayne Syndrome: Type B Glycogen Storage Disease: Type IA 17-Beta-Hydroxysteroid Dehydrogenase Deficiency Cohen Syndrome Glycogen Storage Disease: Type IB 21-Hydroxylase-Deficient Classical Congenital Combined Pituitary Hormone Deficiency: PROP1 Glycogen Storage Disease: Type II Adrenal Hyperplasia Related Glycogen Storage Disease: Type III Glycogen Storage Disease: Type IV 21-Hydroxylase-Deficient Nonclassical Congenital Congenital Disorder of Glycosylation: Type 1A: PMM2 Glycogen Storage Disease: Type V Adrenal Hyperplasia Related Glycogen Storage Disease: Type VII ARSACS Congenital Disorder of Glycosylation: Type 1B: MPI Guanidinoacetate Methyltransferase Deficiency Abetalipoproteinemia Related HMG-CoA Lyase Deficiency Acrodermatitis Enteropathica Congenital Disorder of Glycosylation: Type 1C: ALG6 Hemochromatosis: Type 2A: HFE2 Related Acute Infantile Liver Failure: TRMU Related Related Hemochromatosis: Type 3: TFR2 Related Acyl-CoA Oxidase I Deficiency Congenital Ichthyosis: ABCA12 Related Hemoglobinopathy: Hb C Adenosine Deaminase Deficiency Congenital Insensitivity to Pain with Anhidrosis Hemoglobinopathy: Hb D Adrenoleukodystrophy: X-Linked Congenital Lipoid Adrenal Hyperplasia Hemoglobinopathy: Hb E Alkaptonuria Congenital Myasthenic Syndrome: CHRNE Related Hemoglobinopathy: Hb O Alpha Thalassemia Congenital Myasthenic Syndrome: DOK7 Related Hereditary Fructose Intolerance Alpha-1-Antitrypsin Deficiency Congenital Myasthenic Syndrome: RAPSN Related Hereditary Spastic Paraplegia: TECPR2 Related Alpha-Mannosidosis Congenital Neutropenia: Recessive Herlitz Junctional Epidermolysis Bullosa: LAMA3 Alport Syndrome: COL4A3 Related Copper Transport Disorders Related Alport Syndrome: COL4A4 Related Corneal Dystrophy and Perceptive Deafness Herlitz Junctional Epidermolysis Bullosa: LAMB3 Alport Syndrome: X-linke Corticosterone Methyloxidase Deficiency Related Amegakaryocytic Thrombocytopenia Crigler-Najjar Syndrome Herlitz Junctional Epidermolysis Bullosa: LAMC2 Andermann Syndrome Cystic Fibrosis Related Androgen Insensitivity Syndrome: Complete Cystinosis Hermansky-Pudlak Syndrome: Type 1 Antley-Bixler Syndrome Cystinuria: Non-Type I Hermansky-Pudlak Syndrome: Type 3 Argininemia Cystinuria: Type I Hermansky-Pudlak Syndrome: Type 4 Argininosuccinate Lyase Deficiency D-Bifunctional Protein Deficiency Holocarboxylase Synthetase Deficiency Aromatase Deficiency DMD-Related Muscular Dystrophies Homocystinuria Caused by CBS Deficiency Diabetes: Recessive Permanent Neonatal Hunter Syndrome Arthrogryposis, Mental Retardation, & Seizures Du Pan Syndrome Arts Syndrome Hurler Syndrome Dyskeratosis Congenita: RTEL1 Related Hypohidrotic Ectodermal Dysplasia: X-Linked Asparagine Synthetase Deficiency Dystrophic Epidermolysis Bullosa: Recessive Aspartylglycosaminuria Hypophosphatasia Ehlers-Danlos Syndrome: Type VIIC Inclusion Body Myopathy: Type 2 Ataxia with Vitamin E Deficiency Ellis-van Creveld Syndrome: EVC Related Ataxia-Telangiectasia Infantile Cerebral and Cerebellar Atrophy Ellis-van Creveld Syndrome: EVC2 Related Isolated Microphthalmia: VSX2 Related Autosomal Recessive Polycystic Kidney Disease Emery-Dreifuss Myopathy: X-Linked Isovaleric Acidemia Bardet-Biedl Syndrome: BBS1 Related Enhanced S-Cone Joubert Syndrome Bardet-Biedl Syndrome: BBS10 Related Ethylmalonic Aciduria Juvenile Retinoschisis: X-Linked Bardet-Biedl Syndrome: BBS11 Related Fabry's Disease Lamellar Ichthyosis: Type 1 Bardet-Biedl Syndrome: BBS12 Related Factor II Deficiency Laryngoonychocutaneous Syndrome Bardet-Biedl Syndrome: BBS2 Related Factor IX Deficiency Leber Congenital Amaurosis: CEP290 Related Bare Lymphocyte Syndrome: Type II Factor V Deficiency Leber Congenital Amaurosis: GUCY2D Related Bartter Syndrome: Type 4A Factor V Leiden Thrombophilia Leber Congenital Amaurosis: LCA5 Related Diseases studied by Recombine* Beta Thalassemia Factor VIII Deficiency Leber Congenital Amaurosis: RDH12 Related Beta-Hexosaminidase Pseudodeficiency Factor XI Deficiency Leigh Syndrome: French-Canadian Beta-Ketothiolase Deficiency Familial Chloride Diarrhea Leukoencephalopathy with Vanishing White Matter: Biotinidase Deficiency Familial Dysautonomia EIF2B5 Related Bloom Syndrome Familial Hyperinsulinism: Type 1: ABCC8 Related Leydig Cell Hypoplasia (Luteinizing Hormone Canavan Disease Familial Hyperinsulinism: Type 2: KCNJ11 Related Resistance) Carnitine Palmitoyltransferase IA Deficiency Familial Mediterranean Fever Limb-Girdle Muscular Dystrophy: Type 2A
* The list of genetic diseases may vary according to the laboratory that performs test. Carnitine Palmitoyltransferase II Deficiency Fanconi Anemia: Type A Limb-Girdle Muscular Dystrophy: Type 2B Carnitine-Acylcarnitine Translocase Deficiency Fanconi Anemia: Type C Limb-Girdle Muscular Dystrophy: Type 2C Carpenter Syndrome Fanconi Anemia: Type G Limb-Girdle Muscular Dystrophy: Type 2D Cartilage-Hair Hypoplasia Fanconi Anemia: Type J Limb-Girdle Muscular Dystrophy: Type 2E Cerebrotendinous Xanthomatosis Fragile X Syndrome Limb-Girdle Muscular Dystrophy: Type 2F Charcot-Marie-Tooth Disease with Deafness: Fumarase Deficiency Limb-Girdle Muscular Dystrophy: Type 2I X-Linked: GJB1 Related GM1-Gangliosidoses Lipoprotein Lipase Deficiency Charcot-Marie-Tooth Disease with Deafness: GRACILE Syndrome Diseases studied by Recombine*
Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Niemann-Pick Disease: Type B Retinal Dystrophies: RPE65 Related
Deficiency Niemann-Pick Disease: Type C1 Retinitis Pigmentosa: CERKL Related * The list of genetic diseases may vary according to Lowe Oculocerebrorenal Syndrome Niemann-Pick Disease: Type C2 Retinitis Pigmentosa: DHDDS Related Lysinuric Protein Intolerance Nijmegen Breakage Syndrome Retinitis Pigmentosa: FAM161A Related MTHFR Deficiency Nonsyndromic Hearing Loss and Deafness: GJB2 Rhizomelic Chondrodysplasia Punctata: Type I MTHFR Deficiency: Severe Related SCID: X-Linked Malonyl-CoA Decarboxylase Deficiency Nonsyndromic Hearing Loss and Deafness: LOXHD1 Salla Disease the laboratory that performs test. Maple Syrup Urine Disease: Type 1A Related Sandhoff Disease Maple Syrup Urine Disease: Type 1B Nonsyndromic Hearing Loss and Deafness: MYO15A Sanfilippo Syndrome: Type A Maple Syrup Urine Disease: Type 2 Related Sanfilippo Syndrome: Type B Maple Syrup Urine Disease: Type 3 Oculocutaneous Albinism: Type 1 Sanfilippo Syndrome: Type C Maroteaux-Lamy Syndrome Oculocutaneous Albinism: Type 3 Sanfilippo Syndrome: Type D Meckel Syndrome: Type 1 Oculocutaneous Albinism: Type 4 Short-Chain Acyl-CoA Dehydrogenase Deficiency Medium-Chain Acyl-CoA Dehydrogenase Omenn Syndrome: DCLRE1C Related Sickle-Cell Anemia Deficiency Omenn Syndrome: RAG2 Related Sjogren-Larsson Syndrome Megalencephalic Leukoencephalopathy Ornithine Transcarbamylase Deficiency Sly Syndrome Metachromatic Leukodystrophy Ornithine Translocase Deficiency Smith-Lemli-Opitz Syndrome Methylmalonic Acidemia: MMAA Related Osteopetrosis: TCIRG1 Related Spinal Muscular Atrophy: SMN1 Linked Methylmalonic Acidemia: MMAB Related POLG Related Disorders: Autosomal Recessive Stargardt Disease Methylmalonic Acidemia: MUT Related Papillon-Lefevre Syndrome Stuve-Wiedemann Syndrome Methylmalonic Aciduria and Homocystinuria: Type Pendred Syndrome Sulfate Transporter-Related Osteochondrodysplasia cblC Persistent Mullerian Duct Syndrome: Type I Tay-Sachs Disease Mitochondrial Complex I Deficiency: NDUFS6 Persistent Mullerian Duct Syndrome: Type II Trichohepatoenteric Syndrome: Type 1 Related Phenylalanine Hydroxylase Deficiency Tyrosine Hydroxylase Deficiency Mitochondrial DNA Depletion Syndrome: MNGIE Polyglandular Autoimmune Syndrome: Type I Tyrosinemia: Type I Type Pontocerebellar Hypoplasia: EXOSC3 Related Tyrosinemia: Type II Mitochondrial Myopathy and Sideroblastic Anemia Pontocerebellar Hypoplasia: RARS2 Related Usher Syndrome: Type 1B Mitochondrial Trifunctional Protein Deficiency: Pontocerebellar Hypoplasia: SEPSECS Related Usher Syndrome: Type 1C HADHB Related Pontocerebellar Hypoplasia: TSEN54 Related Usher Syndrome: Type 1D Morquio Syndrome: Type A Pontocerebellar Hypoplasia: VPS53 Related Usher Syndrome: Type 1F Morquio Syndrome: Type B Pontocerebellar Hypoplasia: VRK1 Related Usher Syndrome: Type 2A Mucolipidosis: Type II/III Primary Carnitine Deficiency Usher Syndrome: Type 3 Mucolipidosis: Type IV Primary Ciliary Dyskinesia: DNAI1 Related Very Long-Chain Acyl-CoA Dehydrogenase Multiple Pterygium Syndrome Primary Ciliary Dyskinesia: DNAI2 Related Deficiency Multiple Sulfatase Deficiency Primary Congenital Glaucoma Walker-Warburg Syndrome Muscle-Eye-Brain Disease Primary Hyperoxaluria: Type 1 Werner Syndrome Myotubular Myopathy: X-Linked Primary Hyperoxaluria: Type 2 Wilson Disease Navajo Neurohepatopathy Primary Hyperoxaluria: Type 3 Wiskott-Aldrich Syndrome Nemaline Myopathy: NEB Related Progressive Familial Intrahepatic Cholestasis: Type 2 Wolcott-Rallison Syndrome Nephrotic Syndrome: Type 1 Propionic Acidemia: PCCA Related Wolman Disease Nephrotic Syndrome: Type 2 Propionic Acidemia: PCCB Related Xeroderma Pigmentosum: Group A Neuronal Ceroid-Lipofuscinosis: CLN5 Related Pseudocholinesterase Deficiency Xeroderma Pigmentosum: Group C Neuronal Ceroid-Lipofuscinosis: CLN6 Related Pycnodysostosis Zellweger Spectrum Disorders: PEX1 Related Neuronal Ceroid-Lipofuscinosis: CLN8 Related Pyruvate Carboxylase Deficiency Zellweger Spectrum Disorders: PEX10 Related Neuronal Ceroid-Lipofuscinosis: MFSD8 Related Pyruvate Dehydrogenase Deficiency Zellweger Spectrum Disorders: PEX2 Related Neuronal Ceroid-Lipofuscinosis: PPT1 Related Pyruvate Dehydrogenase Deficiency: X-Linked Zellweger Spectrum Disorders: PEX6 Related Neuronal Ceroid-Lipofuscinosis: TPP1 Related Renal Tubular Acidosis and Deafness Niemann-Pick Disease: Type A Retinal Dystrophies: RLBP1 Related 9
11-Beta-Hydroxylase-Deficient Congenital Adrenal FKRP-Related Disorders (FKRP) Mucopolysaccharidosis, Type IIIC (HGSNAT) Hyperplasia (CYP11B1) FKTN-Related Disorders (including Muscle-Eye-Brain Disease (POMGNT1) 21-Hydroxylase-Deficient Congenital Adrenal Walker-Warburg Syndrome) (FKTN) MUT-Related Methylmalonic Acidemia (MUT) Hyperplasia (CYP21A2)* Fragile X Syndrome (FMR1)* MYO7A-Related Disorders (MYO7A) 6-Pyruvoyl-Tetrahydropterin Synthase Deficiency Galactokinase Deficiency (GALK1) NEB-Related Nemaline Myopathy (NEB) (PTS) Galactosemia (GALT) Niemann-Pick Disease, Type C (NPC1) ABCC8-Related Hyperinsulinism (ABCC8) Gamma-Sarcoglycanopathy (SGCG) Niemann-Pick Disease, Type C2 (NPC2)
Adenosine Deaminase Deficiency (ADA) Gaucher Disease (GBA)* Niemann-Pick Disease, SMPD1-Associated (SMPD1) * The list of genetic diseases may vary according to the laboratory that performs test. Adrenoleukodystrophy: X-Linked (ABCD1) GJB2-Related DFNB1 Nonsyndromic Nijmegen Breakage Syndrome (NBN) Alpha Thalassemia (HBA1/HBA2)* Hearing Loss and Deafness (including two GJB6 Northen Epilepsy (CLN8) Alpha-Mannosidosis (MAN2B1) deletions) (GJB2) Ornithine Transcarbamylase Deficiency (OTC) Alpha-Sarcoglycanopathy (including Limb-Girdle GLB1-Related Disorders (GLB1) PCCA-Related Propionic Acidemia (PCCA) Muscular Dystrophy, Type 2D) (SGCA) GLDC-Related Glycine Encephalopathy (GLDC) PCCB-Related Propionic Acidemia (PCCB) Alport Syndrome, X-Linked (COL4A5) Glutaric Acidemia, Type 1 (GCDH) PCDH15-Related Disorders (including Usher
Alstrom Syndrome (ALMS1) Glycogen Storage Disease, Type Ia (G6PC) Syndrome, Type 1F) (PCDH15) Diseases studied by Precongen* AMT-Related Glycine Encephalopathy (AMT) Glycogen Storage Disease, Type Ib (SLC37A4) Pendred Syndrome (SLC26A4) Andermann Syndrome (SLC12A6) Glycogen Storage Disease, Type III (AGL) Peroxisome Biogenesis Disorder, Type 3 (PEX12) Argininemia (ARG1) GNPTAB-Related Disorders (GNPTAB) Peroxisome Biogenesis Disorder, Type 4 (PEX6) Argininosuccinic Aciduria (ASL) GRACILE Syndrome (BCS1L) Peroxisome Biogenesis Disorder, Type 5 (PEX2) ARSACS (SACS) HADHA-Related Disorders (including Long Chain Peroxisome Biogenesis Disorder, Type 6 (PEX10) Aspartylglycosaminuria (AGA) 3-Hydroxyacyl-CoA PEX1-Related Zellweger Syndrome Spectrum (PEX1) Ataxia with Vitamin E Deficiency (TTPA) Dehydrogenase Deficiency) (HADHA) Phenylalanine Hydroxylase Deficiency (PAH) Ataxia-Telangiectasia (ATM) Hb Beta Chain-Related PKHD1-Related Autosomal Recessive Polycystic ATP7A-Related Disorders (ATP7A) Hemoglobinopathy (including Beta Thalassemia and Kidney Disease (PKHD1) Autosomal Recessive Osteopetrosis, Type 1 (TCIRG1) Sickle Cell Disease) (HBB) Polyglandular Autoimmune Syndrome, Type 1 (AIRE) Bardet-Biedl Syndrome, BBS1-Related (BBS1) Hereditary Fructose Intolerance (ALDOB) Pompe Disease (GAA) Bardet-Biedl Syndrome, BBS10-Related (BBS10) Herlitz Junctional Epidermolysis Bullosa, LAMA3-Rela- PPT1-Related Neuronal Ceroid Lipofuscinosis (PPT1) Bardet-Biedl Syndrome, BBS12-Related (BBS12) ted (LAMA3) Primary Carnitine Deficiency (SLC22A5) Bardet-Biedl Syndrome, BBS2-Related (BBS2) Herlitz Junctional Epidermolysis Bullosa, LAMB3-Rela- Primary Hyperoxaluria, Type 1 (AGXT) Beta-Sarcoglycanopathy (including Limb-Girdle ted (LAMB3) Primary Hyperoxaluria, Type 2 (GRHPR) Muscular Dystrophy, Type 2E) (SGCB) Herlitz Junctional Epidermolysis Bullosa, LAMC2-Rela- Primary Hyperoxaluria, Type 3 (HOGA1) Biotinidase Deficiency (BTD) ted (LAMC2) PROP1-Related Combined Pituitary Hormone Bloom Syndrome (BLM) Hexosaminidase A Deficiency (including Tay-Sachs Deficiency (PROP1) Calpainopathy (CAPN3) Disease) (HEXA) Pycnodysostosis (CTSK) Canavan Disease (ASPA) HMG-CoA Lyase Deficiency (HMGCL) Pyruvate Carboxylase Deficiency (PC) Carbamoylphosphate Synthetase IDeficiency (CPS1) Holocarboxylase Synthetase Deficiency (HLCS) Rhizomelic Chondrodysplasia Punctata, Type 1 Carnitine Palmitoyltransferase IA Homocystinuria caused by Cystathionine Beta-Syn- (PEX7) Deficiency (CPT1A) thase Deficiency (CBS) RTEL1-Related Disorders (RTEL1) Carnitine Palmitoyltransferase II Deficiency (CPT2) Hydrolethalus Syndrome (HYLS1) Salla Disease (SLC17A5) Cartilage-Hair Hypoplasia (RMRP) Hypophosphatasia, Autosomal Recessive (ALPL) Sandhoff Disease (HEXB) Cerebrotendinous Xanthomatosis (CYP27A1) Inclusion Body Myopathy 2 (GNE) Segawa Syndrome (TH) Citrullinemia, Type 1 (ASS1) Isovaleric Acidemia (IVD) Short Chain Acyl-CoA Dehydrogenase Deficiency CLN3-Related Neuronal Ceroid Lipofuscinosis (CLN3) Joubert Syndrome 2 (TMEM216) (ACADS) CLN5-Related Neuronal Ceroid Lipofuscinosis (CLN5) KCNJ11-Related Familial Hyperinsulinism (KCNJ11) Sjogren-Larsson Syndrome (ALDH3A2) CLN6-Neuronal Ceroid Lipofuscinosis, Type 6 (CLN6) Krabbe Disease (GALC) Smith-Lemli-Opitz Syndrome (DHCR7) Cohen Syndrome (VPS13B) LAMA2-Related Muscular Dystrophy (LAMA2) Spastic Paraplegia, Type 15 (ZFYVE26) COL4A3-Related Alport Syndrome (COL4A3) Leigh Syndrome, French-Canadian Type (LRPPRC) Spinal Muscular Atrophy (SMN1)* COL4A4-Related Alport Syndrome (COL4A4) Lipoamide Dehydrogenase Deficiency (DLD) Spondylothoracic Dysostosis (MESP2) Congenital Disorder of Glycosylation, Type la (PMM2) Lipoid Congenital Adrenal Hyperplasia (STAR) Steroid-Resistant Nephrotic Syndrome (NPHS2) Congenital Disorder of Glycosylation, Type lb (MPI) Lysosomal Acid Lipase Deficiency (LIPA) Sulfate Transporter-Related Osteochondrodysplasia Congenital Disorder of Glycosylation, Type lc (ALG6) Maple Syrup Urine Disease, Type Ia (BCKDHA) (SLC26A2) Congenital Finnish Nephrosis (NPHS1) Maple Syrup Urine Disease, Type IB (BCKDHB) TGM1-Related Autosomal Recessive Congenital Costeff Optic Atrophy Syndrome (OPA3) Maple Syrup Urine Disease, Type II (DBT) Ichthyosis (TGM1) Cystic Fibrosis (CFTR) Medium Chain Acyl-CoA Dehydrogenase Deficien- TPP1-Related Neuronal Ceroid Lipofuscinosis (TPP1) Cystinosis (CTNS) cy (ACADM) Tyrosinemia, Type I (FAH) D-Bifunctional Protein Deficiency (HSD17B4) Megalencephalic Leukoencephalopathy with Tyrosinemia, Type II (TAT) Delta-Sarcoglycanopathy (SGCD) Subcortical Cysts (MLC1) USH1C-Related Disorders (USH1C) Dysferlinopathy (DYSF) Metachromatic Leukodystrophy (ARSA) USH2A-Related Disorders (USH2A) Dystrophinopathies (including Duchenne / Becker Methylmalonic Acidemia, cblA Type (MMAA) Usher Syndrome, Type 3 (CLRN1) Muscular Dystrophy) (DMD) Methylmalonic Acidemia, cblB Type (MMAB) Very Long Chain Acyl-CoA Dehydrogenase ERCC6-Related Disorders (ERCC6) Methylmalonic Aciduria and Homocystinuria, cblC Deficiency (ACADVL) ERCC8-Related Disorders (ERCC8) Type (MMACHC) Wilson Disease (ATP7B) EVC-Related Ellis-Van Creveld Syndrome (EVC) MKS1-Related Disorders (MKS1) X-Linked Congenital Adrenal Hypoplasia (NR0B1) EVC2-Related Ellis-Van Creveld Syndrome (EVC2) Mucolipidosis III Gamma (GNPTG) X-Linked Juvenile Retinoschisis (RS1) Fabry Disease (GLA) Mucolipidosis IV (MCOLN1) X-Linked Myotubular Myopathy (MTM1) Familial Dysautonomia (IKBKAP) Mucopolysaccharidosis, Type I X-Linked Severe Combined Immunodeficiency Familial Mediterranean Fever (MEFV) (including Hurler Syndrome) (IDUA) (IL2RG) Fanconi Anemia Complementation, Group A Mucopolysaccharidosis, Type II (IDS) Xeroderma Pigmentosum, Group A (XPA) (FANCA) Mucopolysaccharidosis, Type IIIA (SGSH) Xeroderma Pigmentosum, Group C (XPC) Fanconi Anemia, Type C (FANCC) Mucopolysaccharidosis, Type IIIB (NAGLU) Types of samples
Ovobank makes available to the collaborating centers different types of oocyte batches, thus responding effectively to all your needs, since they will be available to you in most cases within 24/48 hours. We only send vitrified oocytes, in Metaphase II, after a very thorough quality screening that guarantees an optimal morphological quality.
Mini-batch Batch Maxi-batch Embryos
Between 3 and 4 Between 6 and 7 Between 8 and 9 1-2 at vitrified eggs vitrified eggs vitrified eggs blastocyst stage
*We adapt to the needs of each collaborating center for the obtainment of the batches.
10 Embryos shipment
It is a service that we offer to the collaborating centers and patients who wish to leave to Ovobank the attainment of their embryos, guaranteeing at least one in the blastocyst stage.
Protocol of action
The same data is requested as with oocyte requests. The semen from the partner or donor will be selected and thawed and the Ovobank oocytes will be fertilized and cultured in one our assited reproduction centers (Fiv Marbella or Ovoclinic), until blastocyst stage and the resulting blastocysts will be vitrified for later shipment.
Ovobank - The first european donor egg bank Types of shipping
For its shipments, Ovobank uses special boxes for cell trasnport, designed in our facilities by our R&D department. They provide an extra protection for the Dry Shippers containers, approved for this purpose, that contain the oocytes. In addition, during the journey, it is possible to check and download all shipping conditions through the Ovotracker system (GPS position, internal and external temperature, pressure and humidity). We make different types of delivery, always adapted to the requirements of the collaborating centers:
Courier service / Air-terrestrial A specialized courier COURIER company will be responsible of delivering the batches to the collaborating center within a maximum of 24 or 48 hours. 11
Air Lab2Lab
Ovobank qualified personnel and trained for this purpose will be responsible for the transport in the airplane cabin avoiding X-Rays. Therefore we guarantee hand delivery from our Lab to the collaborating center´s Lab.
Terrestrial Lab2Lab
This modality of shipping is also hand delivered by Ovobank qualified personnel in a vehicle specially adapted for the transport of cryopreserved cells, in this case by land.
www.ovobank.com Safety Traceability Tranquility Reliability
The only telematic system of traceability for the delivery of oocytes, sperm and embryos ovotracker.ovobank.com
Ovotracker is a pioneering system created by our D+I Department for monitoring each of the stages through which an egg passes from request 12 receipt at ovobank until it reaches its destination. In addition, the collaboratoring center can place oocyte orders they require through the application and Ovobank website, as well as download the relevant reports thereby speeding up the process and minimizing human errors.
For the first time a complete traceability in the health sector is applied, representing a total innovation in this field. Thanks to the app, it is possible to know parameters at real time such as temperature, humidity, pressure or GPS position of each batch, fully automating the process.
Ovobank - The first european donor egg bank ovomatch
“If I perform an egg donation treatment, will my baby look like me?”
When a couple (or woman without a male partner) decides to go through an egg donation treatment, the question that may be of most concern to you is whether your future baby will physically resemble you. The matching work done by our team, who take into account phenotypic traits, blood group, etc., is now complemented with our facial recognition technology. Ovomatch scans multiple facial points and compares them, thanks to a mathematical facial recognition algorithm, with our extensive database to find donors that more closely ressemble the recipients. Anonymity is fully guaranteed, but the selected donor, as well as a phenotypic compatibility, will have a high facial resemblance to the recipient patient, selecting the donor based on an objective process. Facial recognition technology, at the service of treatments done with Ovobank oocytes 13
Ovomatch scans the reference points of the face to choose the donor with the closest resemblance
www.ovobank.com Ovobank training
Ovobank also means continuous training, both for our team (embryologists, doctors, nurses, etc.) and for the collaborating centers that wish to do so. Periodically, we convene work sessions in our facilities aimed at professionals, to improve their management of our protocols (vitrification, devitrification, endometrial preparation, etc.), studied and optimized to offer the best performance. Because we believe the best way to continuously increase the success rates obtained 14 from our vitrified oocytes is through training.
Contact Always in contact with our large team of coordinators from Ovobank has a wide team of coordinators within the the Department of Collaborating Center Service Department, always available Collaborator Care to solve any doubt or incidence they may have, speaking a Center Attention variety of languages such as Spanish, Italian, Portuguese or English. This Department manages and follows up on the requests for oocytes and embryos from centers around the world.
Ovobank - The first european donor egg bank The Universal Warming Protocol
Ovobank continuously studies the viability of its vitrified oocytes and the freeze-thaw protocols to which they are subjected. Thanks to that, and always thinking about the continuous improvement of the results of our collaborating centers, Ovobank initiated a study based on the "Universal Warming Protocol" in which we tested the effects of the freezing of oocytes using the media of a given manufacturer and its subsequent thawing using media from other manufacturers. As a result of this study we concluded that we could vitrify oocytes with media from a given commercial house and thaw them with media from other brands without the survival rates being affected. This study, which is aimed at further improving the techniques of devitrification, is constantly being updated, and its findings are regularly sent to our collaborating centers, so that they can be applied in their work with Ovobank oocytes. In addition, our laboratory team, headed by our Director Enrique Criado Scholz, has been invited to present the conclusions of this study at congresses de países como Italia, Portugal o Polonia.
Universal Warming Protocol with donor vitrified oocytes (1677 FIV oocytes Marbella 04/30/2018)
VITRIFICATION THAWING NER OOCYTES SURVIVED OOCYTES % DEGENERATED
KITAZATO KITAZATO 886 826 93 % 60
KITAZATO IRVINE 270 235 87 % 35
KITAZATO SAGE 186 179 96 % 7
KITAZATO OMNI VITROLIFE 335 325 97 % 10
15
www.ovobank.com Quality and ethics
At Ovobank we understand that quality must be one of the basic pillars that permeates all our decisions and initiatives. Ovobank, in its eagerness to guarantee the quality and traceability of its work, has achieved the ISO 9001: 2015 Certificate in integral management of a donors egg and sperm bank, audited by Bureau Veritas. FIV Marbella, as the center on which Ovobank is supported, has also been endorsed with this certification. In addition, we have the quality certificate of the prestigious Italian entity Artemide S.R.L., after successfully surpassing the audit carried out in relation to our egg donation process and its subsequent distribution.
R & D at Ovobank
Ovobank means continuous innovation. Our team is always in constant evolution, formulating new protocols, researching, attending the most important congresses in the world... All of this in order to continue learning and contributing with their knowledge to the scientific community. Only in this way is it possible to offer our collaborating centers and patients a service with the highest quality standards, working every day to improve survival, pregnancy and blastulation rates.
16
Ovobank - The first european donor egg bank Fresh Vs. Vitrified Eggs
- Search of donors - Protocol of selection - Psycological test - Medical test Time No waiting list - Blood test (hormone, serology, genetics) - Ecografics controls Necesary synchronasation Does not require Cycle preparation with the recipient synchronazation
Limited Pool of donors Big pool of donors
Difficult to find Dificult phenotypes Available donors
Mature oocytes Un-certain recovered Always 6-7 mature oocytes
Cycle cancelation Round about 15% rates 0%
- Tests, analytics, etc. - Medication Considerable reduction Costs - Egg retrieval of costs 17 - Economic compensation
Limited Availability 100%
Increases by decreasing Waiting list Patient recruitment the necessary time for treatment
www.ovobank.com
Success rates
Pregnancy rates with donor devitrified oocytes do not Survival 1 differ from the rates obtained in an oocyte treatment with rate fresh oocytes. Thanks to the improvement of the vitrification protocols, with the application of the Universal Warming Protocol, in recent years the cryopreservation of 93% oocytes has become possible with a survival rate that approaches 100%.
Ovobank provides only mature oocytes for fertilization with sperm. Thanks to the experience gained and the results obtained, by strictly follwing the Ovobank recommended 86% protocols, from a batch of 6-7 vitrified oocytes, we can guarantee that at least 2 embryos in normal development stage on day 3 will be able to be transferred with a high Pregnancy 2 probability of success. rate
1. Data obtained from our FIV Marbella collaborating centers in 2016 and 2017, following the devitrification protocols recommended by the media manufacturers. 2. β-HCG+ transferring 2 blastocysts.
Endometrial preparation 18
At Ovobank, we know that the state of the endometrium of the patient receiving the egg donation treatment is as important as the quality of the embryos themselves. Therefore, Ovobank has a highly structured endometrial preparation protocol for oocyte receptors available to our collaborating centers, which can be downloaded from the web.
Ovobank - The first european donor egg bank Frequent questions
How does Ovobank work?
As we explained on page 3, first, both patients and collaborating centers must fill out a form with the physical characteristics and blood group of the recipient patients (or patient). The Donor Coordination Department will assign the most compatible donor, both phenotypically and immunologically, and make a proposal. You can have your egg request in the center where the treatment will be done in 24/48 hours in the case of vitrified oocytes.
How far in advance must the request be made? As soon as possible to coordinate the shipment on time to perform the treatment.
Is it possible that we do not have the ideal donor for the recipient couple?
Ovobank has worked hard to obtain a very broad pool of donors of all ethnicities and physical characteristics so that the patients of the collaborating clinics do not have to wait for their egg donation treatment, even in the case of rare phenotypes in our territory. We have five donor recruitment centers: Marbella, Malaga, Madrid, Barcelona and Granada.
What are the advantages of collaborating with Ovobank? – Security: we ensure a set number of mature oocytes per batch depending on the type of the sample. The cancellation rate of egg donation treatments will be less than 1%. – Speed: patients do not have to wait to find their donor, or for the tests performed on the donor. The treatment time therefore is substantially reduced. – Diversity: we have a wide range of donors that covers all ethnic groups / characteristics, including rare phenotypes. – More economical. – High rate of embryo freezing: in addition there is a high freezing rate of embryos on day 3.
Is the form of transportation safe? Our oocyte batches are transported in liquid nitrogen Dry Shipper cryo-containers, especially made for the transport of cells and tissues. The oocytes are in turn classified by a system of rods and goblets that allow for the transfer of the batches from the transport tank to your bank without ever losing the cold chain. In addition, with this system it is very easy to identify the batches without harming the temperature conditions. In turn, the cryo-containers are protected by reinforced aluminum boxes to avoid any damage during their transport.
19
www.ovobank.com FIV MARBELLA
Avda. Severo Ochoa, 67 - 29603 Marbella (Málaga) +34 951 087 975 - +34 618 220 680 [email protected] www.ovobank.com
OVOCLINIC MÁLAGA OVOCLINIC MADRID Paseo de la Farola, 5 C/General Oráa, 47 29016 Málaga 28006 Madrid +34 951 506 462 +34 910 052 808
OVOCLINIC BARCELONA OVOCLINIC GRANADA Carrer de Sepúlveda, 125 C/ Jose Luis Perez Pujadas, s/n 08015 Barcelona 18006 Granada +34 93 706 78 49 +34 858 12 49 38
Asociaciones y sociedades médicas Certificados de calidad